Cancer Res Treat.  2023 Jan;55(1):50-60. 10.4143/crt.2021.1086.

Long-term Survivorship and Non-cancer Competing Mortality in Head and Neck Cancer: A Nationwide Population-Based Study in South Korea

• Jung YS
• Lee D
• Jung KW
• Cho H

• KMID: 2537991
• DOI: http://doi.org/10.4143/crt.2021.1086

Abstract

Purpose
As the survival of head and neck cancer (HNC) improves, survivors increasingly confront non-cancer–related deaths. This nationwide population-based study aimed to investigate non-cancer–related deaths in HNC survivors.
Materials and Methods
Data from the Korean Central Cancer Registry were obtained to characterize causes of death, mortality patterns, and survival in patients with HNC between 2006 and 2016 (n=40,890). Non-cancer-related mortality relative to the general population was evaluated using standardized mortality ratios (SMRs). The 5- and 10-year cause-specific competing risks probabilities of death (cumulative incidence function, CIF) and subdistribution hazards ratios (sHR) from the Fine-Gray models were estimated.
Results
Comorbidity-related mortality was frequent in older patients, whereas suicide was predominant in younger patients. The risk of suicide was greater in patients with HNC than in the general population (SMR, 3.1; 95% confidence interval [CI], 2.7 to 3.5). The probability of HNC deaths reached a plateau at 5 years (5-year CIF, 33.9%; 10-year CIF, 39.5%), whereas the probability of non-HNC deaths showed a long-term linear increase (5-year, CIF 5.6%; 10-year CIF, 11.9%). Patients who were male (sHR, 1.56; 95% CI, 1.41 to 1.72), diagnosed with early-stage HNC (localized vs. distant: sHR, 1.86; 95% CI, 1.58 to 2.21) and older age (65-74 vs. 0-44: sHR, 6.20; 95% CI, 4.92 to 7.82; ≥ 75 vs. 0-44: sHR, 9.81; 95% CI, 7.76 to 12.39) had an increased risk of non-cancer mortality.
Conclusion
Non-HNC–related deaths continue increasing. HNC survivors are at increased risk of suicide in the younger and comorbidity-related death in the older. Better population-specific surveillance awareness and survivorship plans for HNC survivors are warranted.

Keyword

Head and neck neoplasms; Competing risk; Non-cancer death; Mortality; Suicide; Cancer surveillance; Survivorship

Figure

• 

  Fig. 1 Probabilities of survival, death from head and neck cancer and competing other causes by age group (yr). The probabilities of death were estimated by the cumulative incidence function.

• 

  Fig. 2 (A–C) Competing risks probabilities of death from the head and neck cancer and other causes by age and tumor stage.

Reference

References

1. Hall SF, Groome PA, Rothwell D. The impact of comorbidity on the survival of patients with squamous cell carcinoma of the head and neck. Head Neck. 2000; 22:317–22.

2. Baxi SS, Pinheiro LC, Patil SM, Pfister DG, Oeffinger KC, Elkin EB. Causes of death in long-term survivors of head and neck cancer. Cancer. 2014; 120:1507–13.

3. Kim YJ, Kim JH. Increasing incidence and improving survival of oral tongue squamous cell carcinoma. Sci Rep. 2020; 10:7877.

4. Nguyen NA, Ringash J. Head and neck cancer survivorship care: a review of the current guidelines and remaining unmet needs. Curr Treat Options Oncol. 2018; 19:44.

5. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010; 15:994–1001.

6. Simpson MC, Massa ST, Boakye EA, Antisdel JL, Stamatakis KA, Varvares MA, et al. Primary cancer vs competing causes of death in survivors of head and neck cancer. JAMA Oncol. 2018; 4:257–9.

7. Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, et al. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010; 28:15–20.

8. Massa ST, Osazuwa-Peters N, Christopher KM, Arnold LD, Schootman M, Walker RJ, et al. Competing causes of death in the head and neck cancer population. Oral Oncol. 2017; 65:8–15.

9. Kim YH, Roh JL, Kim SB, Choi SH, Nam SY, Kim SY. Risk factors for competing non-cancer mortality after definitive treatment for advanced-stage head and neck cancer. Oral Dis. 2018; 24:1217–25.

10. Shen W, Sakamoto N, Yang L. Cancer-specific mortality and competing mortality in patients with head and neck squamous cell carcinoma: a competing risk analysis. Ann Surg Oncol. 2015; 22:264–71.

11. Vaisanen JA, Alho OP, Koivunen PT, Laara E. Cause-specific mortality in patients with head and neck cancer: long-term follow-up of a population-based cohort from 1986 to 2012 accounting for competing risks. Oral Oncol. 2018; 79:20–6.

12. Gimeno-Hernandez J, Iglesias-Moreno MC, Gomez-Serrano M, Carricondo F, Gil-Loyzaga P, Poch-Broto J. The impact of comorbidity on the survival of patients with laryngeal squamous cell carcinoma. Acta Otolaryngol. 2011; 131:840–6.

13. Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000; 110:593–602.

14. Paleri V, Wight RG, Davies GR. Impact of comorbidity on the outcome of laryngeal squamous cancer. Head Neck. 2003; 25:1019–26.

15. Boje CR, Dalton SO, Primdahl H, Kristensen CA, Andersen E, Johansen J, et al. Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. Radiother Oncol. 2014; 110:91–7.

16. Hess CB, Rash DL, Daly ME, Farwell DG, Bishop J, Vaughan AT, et al. Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy. JAMA Otolaryngol Head Neck Surg. 2014; 140:312–6.

17. Laara E, Korpi JT, Pitkanen H, Alho OP, Kantola S. Competing risks analysis of cause-specific mortality in patients with oral squamous cell carcinoma. Head Neck. 2017; 39:56–62.

18. Forastiere AA, Weber RS, Trotti A. Organ preservation for advanced larynx cancer: issues and outcomes. J Clin Oncol. 2015; 33:3262–8.

19. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014; 32:2735–43.

20. Lop J, Garcia J, Lopez M, Taberna M, Mena M, Alemany L, et al. Competing mortality in oropharyngeal carcinoma according to human papillomavirus status. Head Neck. 2019; 41:1328–34.

21. Norregaard C, Gronhoj C, Jensen D, Friborg J, Andersen E, von Buchwald C. Cause-specific mortality in HPV+ and HPV− oropharyngeal cancer patients: insights from a population-based cohort. Cancer Med. 2018; 7:87–94.

22. Choi JW, Park EC. Suicide risk after cancer diagnosis among older adults: a nationwide retrospective cohort study. J Geriatr Oncol. 2020; 11:814–9.

23. Zaorsky NG, Zhang Y, Tuanquin L, Bluethmann SM, Park HS, Chinchilli VM. Suicide among cancer patients. Nat Commun. 2019; 10:207.

24. Jung YS, Lim J, Jung KW, Ryu J, Won YJ. Metachronous second primary malignancies after head and neck cancer in a Korean cohort (1993–2010). PLoS One. 2015; 10:e0134160.

25. Shin A, Jung YS, Jung KW, Kim K, Ryu J, Won YJ. Trends of human papillomavirus-related head and neck cancers in Korea: national cancer registry data. Laryngoscope. 2013; 123:E30–7.

26. Kwon M, Roh JL, Song J, Lee SW, Kim SB, Choi SH, et al. Noncancer health events as a leading cause of competing mortality in advanced head and neck cancer. Ann Oncol. 2014; 25:1208–14.

27. Takenaka Y, Yasui T, Enomoto K, Miyabe H, Morizane N, Ashida N, et al. Risk factors associated with competing mortality among patients with head and neck cancer in Japan. Acta Otolaryngol. 2016; 136:325–9.

28. Jung KW, Won YJ, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat. 2019; 51:417–30.

29. World Health Organization. International statistical classifi-cation of diseases and related health problems. Geneva: World Health Organization;2004.

30. Shin HY, Lee JY, Song J, Lee S, Lee J, Lim B, et al. Cause-of-death statistics in the Republic of Korea, 2014. J Korean Med Assoc. 2016; 59:221–32.

31. Cho H, Mariotto AB, Mann BS, Klabunde CN, Feuer EJ. Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Am J Epidemiol. 2013; 178:339–49.

32. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010; 102:1584–98.

33. Kahn HA, Sempos CT. Statistical methods in epidemiology. New York: Oxford University Press;1989.

34. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978; 34:541–54.

35. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16:1141–54.

36. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94:496–509.

37. Simpson WG, Klaassen Z, Jen RP, Hughes WM, Neal DE Jr, Terris MK. Analysis of suicide risk in patients with penile cancer and review of the literature. Clin Genitourin Cancer. 2018; 16:e257–61.

38. Coatesworth AP, Tsikoudas A, MacLennan K. The cause of death in patients with head and neck squamous cell carcinoma. J Laryngol Otol. 2002; 116:269–71.

39. Rose BS, Jeong JH, Nath SK, Lu SM, Mell LK. Population-based study of competing mortality in head and neck cancer. J Clin Oncol. 2011; 29:3503–9.

40. Zapata I, Alvarez M, Hidalgo R, Pajares B, Garcia-Anaya MJ, Toledo MD, et al. Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy. BMC Cancer. 2019; 19:1241.

41. Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, et al. Causes of death among cancer patients. Ann Oncol. 2017; 28:400–7.

42. Pignon JP, le Maitre A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92:4–14.

43. Stoltzfus KC, Zhang Y, Sturgeon K, Sinoway LI, Trifiletti DM, Chinchilli VM, et al. Fatal heart disease among cancer pati-ents. Nat Commun. 2020; 11:2011.

44. Zaorsky NG, Zhang Y, Tchelebi LT, Mackley HB, Chinchilli VM, Zacharia BE. Stroke among cancer patients. Nat Commun. 2019; 10:5172.

45. Statistics Korea. Population projections for Korea: 2015–2065 (based on the 2015 population census). Daejeon: Statistics Korea;2016.

46. Bank of Korea, Economic Research Institute. Population aging: impacts and policy imperatives. Seoul: Bank of Korea, Economic Research Institute;2017.

47. Osazuwa-Peters N, Simpson MC, Zhao L, Boakye EA, Olomukoro SI, Deshields T, et al. Suicide risk among cancer survivors: head and neck versus other cancers. Cancer. 2018; 124:4072–9.

48. Oh CM, Lee D, Kong HJ, Lee S, Won YJ, Jung KW, et al. Causes of death among cancer patients in the era of cancer survivorship in Korea: attention to the suicide and cardiovascular mortality. Cancer Med. 2020; 9:1741–52.

49. World Health Organization. Suicide rates, age-standardized data by country. Geneva: World Health Organization;2015.

50. Cain G. Why Koreans are killing themselves in droves [Internet]. Boston, MA: The World;2014. [cited 2022 May 30]. Available from: https://theworld.org/stories/2014-03-13/why-koreans-are-killing-themselves-droves .

51. Semple CJ, Sullivan K, Dunwoody L, Kernohan WG. Psychosocial interventions for patients with head and neck cancer: past, present, and future. Cancer Nurs. 2004; 27:434–41.

52. Howren MB, Christensen AJ, Karnell LH, Funk GF. Psychological factors associated with head and neck cancer treatment and survivorship: evidence and opportunities for behavioral medicine. J Consult Clin Psychol. 2013; 81:299–317.

53. Murphy BA, Deng J. Advances in supportive care for late effects of head and neck cancer. J Clin Oncol. 2015; 33:3314–21.

54. Poorolajal J, Haghtalab T, Farhadi M, Darvishi N. Substance use disorder and risk of suicidal ideation, suicide attempt and suicide death: a meta-analysis. J Public Health (Oxf). 2016; 38:e282–91.

55. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363:24–35.

56. Cohen EE, LaMonte SJ, Erb NL, Beckman KL, Sadeghi N, Hutcheson KA, et al. American Cancer Society head and neck cancer survivorship care guideline. CA Cancer J Clin. 2016; 66:203–39.